Balancing Risks: Antiplatelet Therapy After Intracerebral Haemorrhage in the STATICH Trial
Highlight
- The STATICH trial evaluated antiplatelet treatment safety after spontaneous intracerebral hemorrhage (ICH).
- Patients starting antiplatelet therapy had numerically more recurrent hemorrhages but fewer major ischemic events.
- The trial was terminated early due to slow recruitment, limiting definitive conclusions.
- Results will inform a collaborative meta-analysis to guide post-ICH antithrombotic management.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.